

Datasheet for 600-401-K09S**SMAD2 phospho S465/phospho S467 Antibody****Overview**

Description:	Anti-SMAD2 pS465 pS467 (RABBIT) Antibody - 600-401-K09S
Item No.:	600-401-K09S
Size:	25 µL
Applications:	ELISA, WB
Reactivity:	Human
Host Species:	Rabbit

Product Details

Background:	Smad2 is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI). Smad2 (Mothers against decapentaplegic homolog 2) is a member of the Smad family of proteins which are similar to the gene products of the Drosophila gene 'mothers against decapentaplegic' (Mad) and the C. elegans gene Sma. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways. This protein mediates the signal of the transforming growth factor (TGF)-beta, and thus regulates multiple cellular processes, such as cell proliferation, apoptosis, and differentiation. This protein is recruited to the TGF-beta receptors through its interaction with the SMAD anchor for receptor activation (SARA) protein. In response to TGF-beta signal, this protein is phosphorylated by the TGF-beta receptors. The phosphorylation induces the dissociation of this protein with SARA and the association with the family member SMAD4. The association with SMAD4 is important for the translocation of this protein into the nucleus, where it binds to target promoters and forms a transcription repressor complex with other cofactors. Anti-SMAD2 pS465 pS467 antibody is ideal for researchers interested in Cancer, Immunology and Nuclear Signaling research.
Synonyms:	rabbit anti-SMAD2 pS465pS467 antibody, SMAD-2, SMAD 2, mothers against decapentaplegic homolog 2 antibody, MAD homolog 2, Mothers against DPP homolog 2, SMAD family member 2, MADH2, MADH 2, JV18-1
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	SMAD2
Reactivity:	Human
PTM Specificity:	Dual Modification
Immunogen Type:	Conjugated Peptide
Immunogen:	SMAD2 pS465 pS467 antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic phospho-peptide corresponding to a C-terminal of human SMAD2 protein.
Purity/Specificity:	Anti-SMAD2 pS465 pS467 antibody is directed against the phosphorylated form of human Smad2 protein at the pS465 and pS467 residues. The product was affinity purified from monospecific antiserum by immunoaffinity purification. Antiserum was first purified against the phosphorylated form of the immunizing peptide. The resultant affinity purified antibody was then cross adsorbed against the non-phosphorylated form of the immunizing peptide. Reactivity occurs against human SMAD2. Reactivity with non-phosphorylated human Smad2 is minimal by ELISA and western blot. A BLAST analysis was used to suggest cross-reactivity with Smad2 protein from human, mouse, rat, orangutan, and bovine based on 100% homology with the immunizing sequence. Reactivity against homologues from other sources is not known.
Relevant Links:	NCBI - 5174511 UniProtKB - Q15796 GenelD - 4087

Application Details

Tested Applications:	ELISA, WB
Application Note:	Anti-SMAD2 pS465 pS467 affinity purified antibody has been tested for use in ELISA and western blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 52 kDa in size corresponding to Smad2 protein by western blotting in the appropriate cell lysate or extract.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:10,000
WB:	1:1,000 - 1:3,000


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	0.94 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling


Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20° C or below prior to opening. This vial contains a relatively low volume of reagent (25 µL). To minimize loss of volume dilute 1:10 by adding 225 µL of the buffer stated above directly to the vial. Recap, mix thoroughly and briefly centrifuge to collect the volume at the bottom of the vial. Use this intermediate dilution when calculating final dilutions as recommended below. Store the vial at -20°C or below after dilution. Avoid cycles of freezing and thawing.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



Western Blot

(B) Macrophages were stimulated with 2 ng/ml recombinant TGF-β for 30 minutes. TGF-βRII deletion led to decreases in TGF-β-stimulated phosphorylation of Smad2 and Smad3, an indication of TGF-βRII deficiency. Smad2 (p/n 600-401-A59); p-Smad3, phospho-Smad3 (p/n 600-401-919); p-Smad2, phospho-Smad2 (p/n 600-401-K09); FAK, focal adhesion kinase. Fig 1. PMID: 30385721



Western Blot

Western Blot of Rabbit anti-Smad2 pS465pS467 antibody.
 Lane 1: MDA-MB-231 cells. Lane 2: MDA-MB-231 cells treated with TGF- β 1 for 1h. Load: 20 μ g per lane. Primary antibody: Smad2pS465pS467 antibody at 1:1000 for overnight at 4°C. Secondary antibody: IRDye800™ rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO/TBST overnight at 4°C. Predicted/Observed size: 52.3 kDa for Smad2pS465pS467. Other band(s): ~85kDa non-specific band.

References

- Chung et al. TGF- β promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. *JCI Insight* (2018)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.